AstraZeneca has invested $2 billion in Summit Therapeutics, acquiring about 12% of its shares and entering a collaboration to develop a cancer drug combining PD-1/VEGF mechanisms. This drug class may outperform existing treatments by activating the immune system and inhibiting tumor blood vessel growth. AstraZeneca will test Summit’s ivonescimab with its own antibody drug conjugate in gastrointestinal cancers, aiming to enhance cancer treatment options. Analysts from UBS and Jefferies view the deal positively, highlighting strategic benefits and upcoming clinical trial results expected in late 2026.
AstraZeneca shares are stable at USD 166.15 with no change in the last day as of Sep 29, 2026 19:23 WIB on Pluang. The stock shows strong investor interest with 98% of order activity on Pluang being buys. AstraZeneca's market cap stands at $256.26 billion, reflecting its significant presence in the health sector.
AstraZeneca is investing $2 billion in Summit Therapeutics to collaborate on cancer drug development, acquiring about 12% of Summit's common stock. The partnership will start clinical trials combining Summit’s ivonescimab with AstraZeneca’s sonesitat...
Anthropic's IPO prospectus reveals serious warnings about AI risks, including potential catastrophic harm and rogue behavior from its models. Despite these risks, the company, known for its Claude chatbot, aims for a $2tn valuation with revenue growi...
AstraZeneca PLC has received EU approval for its asthma treatment Trixeo Aerosphere, expanding its market in Respiratory & Immunology. The company leverages mid-single-digit revenue growth into stronger earnings per share gains, driven by its oncolog...
